Exact claim · Version 1 · Reviewed 2026-07-24
“Retatrutide caused weight loss in a randomized human trial.”
A verdict on this wording and scope, not a universal grade for Retatrutide.
01 · Verdict
Supported with scope
The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults meeting the phase 2 obesity-trial criteria over 48 weeks.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.